A Study to Provide Complementary Efficacy, Safety and Patient Reported Outcomes Data in Participants With Active Relapsing Forms of Multiple Sclerosis (MS) in a Pragmatic Setting

NCT03589105 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

423

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Sclerosis

Interventions

DRUG: Ocrelizumab 300 mg
DRUG: Ocrelizumab 600 mg

Sponsor

Hoffmann-La Roche